Vaccination with a Modified Vaccinia Virus Ankara-based vaccine protects mice from allergic sensitization

Abstract

Background Currently, no treatment is available for food allergy and strict avoidance of the allergenic food remains the only way to manage the allergy. New strategies leading to a safe and efficacious food allergy treatment are required. Modified vaccinia virus Ankara (MVA), which allows high levels of expression of recombinant protein in vivo and gives rise to a Th1‐biased specific immune response, was used as a prophylactic vaccine in a murine model of ovalbumin (OVA) allergy. Methods An MVA‐OVA vector vaccine was prepared. Female BALB/c mice were vaccinated twice with a MVA‐OVA vector vaccine, followed by sensitization with OVA plus alum. OVA‐specific immunoglobulin E(IgE) activity was measured by mediator release from rat basophilic leukaemia cells, whereas specific IgG subclass titers were determined by enzyme‐linked immunosorbent assay. Results Expression of immunological active OVA in mammalian cells was demonstrated. OVA‐specific IgE levels in sera from MVA‐OVA‐vaccinated mice were reduced and appeared delayed. The vaccine‐mediated immune modulation was dose‐dependent; the highest vaccine dose protected 50% of the animals from allergic sensitization. Upon sensitization, similar OVA‐specific IgG1 titers were found in all mice, but the OVA‐specific IgG2a antibody levels were strongly increased in MVA‐OVA‐vaccinated mice, signifying a Th1‐biased and, non‐allergic immune response. Conclusions Prophylactic vaccination with MVA‐OVA delays and in part even prevents the onset of a successful allergen‐specific sensitization. Recombinant MVA, which fulfills the requirements for clinical application, is a promising candidate vector for the development of novel approaches to allergen‐specific prophylactic vaccination and specific immunotherapy. Copyright © 2008 John Wiley & Sons, Ltd.